Motavizumab: Difference between revisions

	WikiDoc Resources for Motavizumab
Articles
Most recent articles on Motavizumab Most cited articles on Motavizumab Review articles on Motavizumab Articles on Motavizumab in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Motavizumab Images of Motavizumab Photos of Motavizumab Podcasts & MP3s on Motavizumab Videos on Motavizumab
Evidence Based Medicine
Cochrane Collaboration on Motavizumab Bandolier on Motavizumab TRIP on Motavizumab
Clinical Trials
Ongoing Trials on Motavizumab at Clinical Trials.gov Trial results on Motavizumab Clinical Trials on Motavizumab at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Motavizumab NICE Guidance on Motavizumab NHS PRODIGY Guidance FDA on Motavizumab CDC on Motavizumab
Books
Books on Motavizumab
News
Motavizumab in the news Be alerted to news on Motavizumab News trends on Motavizumab
Commentary
Blogs on Motavizumab
Definitions
Definitions of Motavizumab
Patient Resources / Community
Patient resources on Motavizumab Discussion groups on Motavizumab Patient Handouts on Motavizumab Directions to Hospitals Treating Motavizumab Risk calculators and risk factors for Motavizumab
Healthcare Provider Resources
Symptoms of Motavizumab Causes & Risk Factors for Motavizumab Diagnostic studies for Motavizumab Treatment of Motavizumab
Continuing Medical Education (CME)
CME Programs on Motavizumab
International
Motavizumab en Espanol Motavizumab en Francais
Business
Motavizumab in the Marketplace Patents on Motavizumab
Experimental / Informatics
List of terms related to Motavizumab

Motavizumab
Monoclonal antibody
Type	Whole antibody
Source	Template:Infobox drug/mab source
Target	RSV glycoprotein F
Clinical data
Trade names	Numax
Routes of; administration	i.v.
ATC code	J06BB17 (WHO) ;
Pharmacokinetic data
Protein binding	None
Identifiers
CAS Number	677010-34-3 ;
ChemSpider	NA ;
UNII	50Y163LK8Q;
KEGG	D06621 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C6476H10014N1706O2008S48
Molar mass	Approximately 148 kDa
(what is this?) (verify)

VisualWikitext

Latest revision as of 13:30, 7 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009^[update], it is undergoing Phase II and III clinical trials.^[1]

In June 2010, the FDA Antiviral Drugs Advisory Committee declined to endorse MedImmune's request for licensure of Motavizumab in a 14 to 3 decision. The members of that panel cited several reasons for the decision, and many were concerned that "we're not looking at a product that has evidence of superiority in terms of efficacy" when compared to the already available monoclonal antibody Palivizumab.^[2]

In December 2010, AstraZeneca in a stock market statement stated that it would be writing down $445m (£286m) after discontinuing a key development programme for Motavizumab. The company stated that it would no longer develop Motavizumab for the prevention of respiratory syncytial virus (RSV), and as a result was withdrawing its licence application to the US Food and Drug Administration. It added that it would continue to develop Motavizumab for other treatments of RSV.^[3]

References

↑ ClinicalTrials.gov
↑ "FDA Panel Nixes Licensing Request for Motavizumab". Medscape. 3 June 2010. Retrieved 2014-03-02.
↑ "AstraZeneca halts work on Motavizumab drug". BBC News. 21 December 2010. Retrieved 2010-12-21.

[1] ClinicalTrials.gov

[2] "FDA Panel Nixes Licensing Request for Motavizumab". Medscape. 3 June 2010. Retrieved 2014-03-02.

[3] "AstraZeneca halts work on Motavizumab drug". BBC News. 21 December 2010. Retrieved 2010-12-21.

[1]

[2]

[3]

@@ Line 1: / Line 1: @@
-{{drugbox-mab
+{{Drugbox
-| image =
+| Verifiedfields = changed
-| source = [[Human]]
+| Watchedfields = changed
-| target =
+| verifiedrevid = 458284116
-| CAS_number        = 677010-34-3
-| ATC_prefix        =
+<!--Monoclonal antibody data-->
-| ATC_suffix        =
+| type = mab
-| PubChem           =
+| mab_type = mab
-| DrugBank          =
+| source = zu/o
-| chemical_formula  =
+| target = [[respiratory syncytial virus|RSV]] glycoprotein F
-| molecular_weight  = Approximately 148 [[Atomic mass unit|kDa]]
-| bioavailability   =
+<!--Clinical data-->
-| protein_bound     =
+| tradename = Numax
-| metabolism        =
+| pregnancy_AU =
-| elimination_half-life =
+| pregnancy_US =
-| excretion         =
+| pregnancy_category =
-| pregnancy_AU      =
+| legal_AU =
-| pregnancy_US      =
+| legal_CA =
-| pregnancy_category=
+| legal_UK =
-| legal_AU          =
+| legal_US =
-| legal_CA          =
+| legal_status =
-| legal_UK          =
+| routes_of_administration = i.v.
-| legal_US          =
-| legal_status      =
+<!--Pharmacokinetic data-->
-| routes_of_administration =
+| bioavailability =
+| protein_bound = None
+| metabolism =
+| elimination_half-life =
+| excretion =
+<!--Identifiers-->
+| CAS_number_Ref = {{cascite|changed|??}}
+| CAS_number = 677010-34-3
+| ATC_prefix = J06
+| ATC_suffix = BB17
+| PubChem =
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
+| DrugBank =
+| UNII_Ref = {{fdacite|correct|FDA}}
+| UNII = 50Y163LK8Q
+| KEGG_Ref = {{keggcite|correct|kegg}}
+| KEGG = D06621
+| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
+| ChemSpiderID = NA
+<!--Chemical data-->
+| C=6476 | H=10014 | N=1706 | O=2008 | S=48
+| molecular_weight = Approximately 148 [[Atomic mass unit|kDa]]
 }}
+__NOTOC__
+{{SI}}
+{{CMG}}
+==Overview==
+'''Motavizumab''' (proposed [[International Nonproprietary Name|INN]], trade name '''Numax''') is a [[humanized monoclonal antibody]]. It is being investigated by [[MedImmune]] (today a subsidiary of [[AstraZeneca]]) for the prevention of [[respiratory syncytial virus]] infection in high-risk [[infant]]s. {{As of|September 2009}}, it is undergoing Phase II and III [[clinical trials]].<ref>[http://www.clinicaltrials.gov/ct2/results?term=motavizumab ClinicalTrials.gov]</ref>
+In June 2010, the FDA Antiviral Drugs Advisory Committee declined to endorse MedImmune's request for licensure of Motavizumab in a 14 to 3 decision. The members of that panel cited several reasons for the decision, and many were concerned that "we're not looking at a product that has evidence of superiority in terms of efficacy" when compared to the already available monoclonal antibody Palivizumab.<ref>{{cite web|url=http://www.medscape.com/viewarticle/722903|title=FDA Panel Nixes Licensing Request for Motavizumab|publisher=Medscape|date=3 June 2010|accessdate=2014-03-02}}</ref>
-'''Motavizumab''' (proposed [[International Nonproprietary Name|INN]], trade name '''Numax''') is a [[Humanize|humanized]] [[monoclonal antibody]]. It is [[As of 2007|currently]] being investigated by [[MedImmune]] for the prevention of [[respiratory syncytial virus]] infection in high-risk [[infant]]s.
+In December 2010, AstraZeneca in a stock market statement stated that it would be writing down $445m (£286m) after discontinuing a key development programme for Motavizumab. The company stated that it would no longer develop Motavizumab for the prevention of [[respiratory syncytial virus]] (RSV), and as a result was withdrawing its licence application to the US [[Food and Drug Administration]]. It added that it would continue to develop Motavizumab for other treatments of RSV.<ref>{{cite web|url=http://www.bbc.co.uk/news/business-12047666|title=AstraZeneca halts work on Motavizumab drug|publisher=BBC News|date=21 December 2010|accessdate=2010-12-21}}</ref>
-==External links==
+==References==
-*[http://www.medimmune.com/pipeline/numax.asp MedImmune]
+{{reflist|2}}
-{{monoclonal-antibody-stub}}
-{{humanizedmonoclonals}}
-[[Category:Monoclonal antibodies]]
+[[Category:AstraZeneca]]
+[[Category:Drug]]

Motavizumab: Difference between revisions

Latest revision as of 13:30, 7 April 2015

Overview

References

Navigation menu